In 1999, the company was founded
In 1999, recognized by the Beijing Municipal Science and Technology Commission, the company was awarded the certificate of Beijing High-tech Enterprise
In 2000, the company produced the first coronary stent system in China, and took the lead in obtaining the registration certificate of China's first domestically produced LPCSRX Coronary Stent Delivery System issued by the State Food and Drug Administration
.In 2001, the LPCSRX Coronary Stent Delivery System was awarded the National Key New Product Certificate
In 2002, the Coronary Stent Delivery System was recognized as the Beijing High-tech Achievement Transformation Project. In 2002, the company started the development of drug-coated stents
In 2003, the company was reorganized to increase capital and expand shares
In 2004, the company's interventional medical core product high-tech industrialization project was included in the National Development and Reform Commission's High Technology Industrialization Demonstration Project Special Plan.
In 2005, "Intravascular Drug (Rapamycin) Eluting Stent System" successfully obtained the product registration certificate and went on sale.
In 2006, "Intravascular Drug (Rapamycin) Eluting Stent System" was awarded the Beijing High-tech Achievement Transformation Project and recognized as a national key new product.
In 2007, the company introduced a strategic investment partner, Brook Investments, Inc.
In 2007, we became the first vascular stent manufacturer in China to pass the pilot inspection and audit of "Good Manufacturing Practice for Implantable Medical Devices" (GMP) by the State Drug Administration.
In 2008, LOPE was restructured and officially renamed as "LOPE (Beijing) Medical Devices Co.
In 2009, LOPE was listed on the Shenzhen Stock Exchange's A-share GEM board under the stock code 300003.
In 2010, LOPE embarked on a new journey .....
Zhejiang New Donggang Pharmaceutical Co., Ltd (New Donggang) was founded in 2001, located in Jiaojiang Park, Taizhou City, which is a national-level export base of chemical APIs in South East Zhejiang Province. In accordance with the development strategy of strong combination, the company introduced a new shareholder, the world's top 500 Zhejiang Material Group, in 2012, and a controlling shareholder, Lepu Medical, in 2014, and became a subsidiary of Lepu Medical. New Donggang is mainly engaged in the research, development, production and sales of anti-infective, cardiovascular and neurological series of drugs, and its leading products are Norfloxacin, Atorvastatin, Rosuvastatin, Meropenem and other APIs, intermediates and preparations. Several varieties of the company have passed GMP, FDA, MHRA, COS, KFDA and other certifications, and hold a position in the international arena.
Hainan Mingshengda Pharmaceuticals Co., Ltd (Mingshengda Pharmaceuticals) is a pharmaceutical service enterprise serving medical institutions and end-users with cardiovascular specialized pharmaceuticals and devices as agent and wholesaler, and has competitive advantages in the layout of varieties of cardiovascular, respiratory and analgesic pharmaceuticals and in channel coverage. LPMC is the controlling shareholder of Mingshengda Pharmaceuticals, holding 68.65% of its shares. Ming Shengda Pharmaceuticals business scope: proprietary Chinese medicines, chemical raw materials, chemical preparations, antibiotics, biochemical drugs sales, pharmaceutical technology transfer. 6846 implantable materials and artificial organs (III, II), 6830 medical X-ray equipment (III, II), 6823 medical ultrasound instruments and related equipment (III, II), 6821 medical electronic instrumentation (III, II), medical device technology, medical device technology. Class II), medical device technology consulting, technology transfer, technical services, technical training, medical equipment leasing.